Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

FMC7 antigen expression on normal and malignant B-cells can be predicted by expression of CD20.

Hübl W, Iturraspe J, Braylan RC.

Cytometry. 1998 Apr 15;34(2):71-4.

PMID:
9579603
2.

Pan B-cell markers are not redundant in analysis of chronic lymphocytic leukemia (CLL).

Monaghan SA, Peterson LC, James C, Marszalek L, Khoong A, Bachta DJ, Karpus WJ, Goolsby CL.

Cytometry B Clin Cytom. 2003 Nov;56(1):30-42.

PMID:
14582135
3.

Diagnostic significance of CD20 and FMC7 expression in B-cell disorders.

Delgado J, Matutes E, Morilla AM, Morilla RM, Owusu-Ankomah KA, Rafiq-Mohammed F, del Giudice I, Catovsky D.

Am J Clin Pathol. 2003 Nov;120(5):754-9.

4.

Flow cytometric immunophenotyping analysis of patterns of antigen expression in non-Hodgkin's B cell lymphoma in samples obtained from different anatomic sites.

Gervasi F, Lo Verso R, Giambanco C, Cardinale G, Tomaselli C, Pagnucco G.

Ann N Y Acad Sci. 2004 Dec;1028:457-62.

PMID:
15650271
5.
6.

GM-CSF does not increase CD20 antigen expression on chronic lymphocytic leukemia lymphocytes.

Yağci M, Akar I, Sucak GT, Haznedar R.

Leuk Res. 2005 Jul;29(7):735-8.

PMID:
15927668
7.

Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.

Chow KU, Sommerlad WD, Boehrer S, Schneider B, Seipelt G, Rummel MJ, Hoelzer D, Mitrou PS, Weidmann E.

Haematologica. 2002 Jan;87(1):33-43.

8.

Detection of subgroups of chronic B-cell leukemias by FMC7 monoclonal antibody.

Huh YO, Pugh WC, Kantarjian HM, Stass SA, Cork A, Trujillo JM, Keating MJ.

Am J Clin Pathol. 1994 Mar;101(3):283-9.

PMID:
8135183
10.

Levels of expression of CD19 and CD20 in chronic B cell leukaemias.

Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Catovsky D.

J Clin Pathol. 1998 May;51(5):364-9.

11.

Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies.

Rossmann ED, Lundin J, Lenkei R, Mellstedt H, Osterborg A.

Hematol J. 2001;2(5):300-6.

PMID:
11920265
12.

MY4 expression on B-lymphocyte malignancies may be associated with a more adverse prognosis.

Warzynski MJ, Otto RN, Steingart RH, White CF, Rosen MH, Hetzel PC, Flatow FA, Podgurski AE, Johnson ML.

Leuk Res. 1991;15(5):357-65.

PMID:
2046387
13.

Effect of interferon-alpha on CD20 antigen expression of B-cell chronic lymphocytic leukemia.

Sivaraman S, Venugopal P, Ranganathan R, Deshpande CG, Huang X, Jajeh A, Gregory SA, O'Brien T, Preisler HD.

Cytokines Cell Mol Ther. 2000 Jun;6(2):81-7.

PMID:
11108573
14.

A cholesterol-dependent CD20 epitope detected by the FMC7 antibody.

Polyak MJ, Ayer LM, Szczepek AJ, Deans JP.

Leukemia. 2003 Jul;17(7):1384-9.

PMID:
12835728
15.

Human Lyb-2 homolog CD72 is a marker for progenitor B-cell leukemias.

Schwarting R, Castello R, Moldenhauer G, Pezzutto A, von Hoegen I, Ludwig WD, Parnes JR, Dörken B.

Am J Hematol. 1992 Nov;41(3):151-8.

PMID:
1384316
16.

Effects of cytokines on CD20 antigen expression on tumor cells from patients with chronic lymphocytic leukemia.

Venugopal P, Sivaraman S, Huang XK, Nayini J, Gregory SA, Preisler HD.

Leuk Res. 2000 May;24(5):411-5.

PMID:
10785263
17.

Higher levels of surface CD20 expression on circulating lymphocytes compared with bone marrow and lymph nodes in B-cell chronic lymphocytic leukemia.

Huh YO, Keating MJ, Saffer HL, Jilani I, Lerner S, Albitar M.

Am J Clin Pathol. 2001 Sep;116(3):437-43.

19.
20.

Prognostic significance of fluorescence intensity of surface marker expression in childhood B-precursor acute lymphoblastic leukemia. A Pediatric Oncology Group Study.

Borowitz MJ, Shuster J, Carroll AJ, Nash M, Look AT, Camitta B, Mahoney D, Lauer SJ, Pullen DJ.

Blood. 1997 Jun 1;89(11):3960-6.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk